- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Anonymous complaint alleged sales reps used an “Oncology Product Pipeline Update” to promote unlicensed products. Panel found reps weren’t instructed to promote…
Astellas voluntarily admitted using incomplete prescribing information across multiple medicines and materials over several years, including omissions of serious/common adverse reactions and…
Novartis retweeted an HCP’s positive tweet about a Novartis haematology meeting. Complaint alleged disguised promotion, public promotion and breach of a prior…
Public complaint alleged excessive HCP payments/business-class travel, misuse of approval stamp, and ignored/outdated SOPs. Panel found no breach on travel/certification, but ruled…
At an HIV conference stand, Gilead promoted Biktarvy with a broad “better tolerated than DTG-containing regimens” claim and rose/thorns imagery. PMCPA ruled…
Ex-employee alleged portfolio “bundling” created an incentive to prescribe Botox. PMCPA found the arrangements were terms of trade (prices/discounts) exempt under Clause…
Ex-employee complaint about meetings (2008–2009). Off-licence promotion not proven, but excessive restaurant hospitality and ethical conduct failures were found. Appeal added breaches…
Baxter admitted some representatives had not taken the ABPI Medical Representatives Examination within their first year. The Panel found a breach of…
A BHIVA conference booklet ad for Prezista lacked prescribing information and used a once-daily dosing claim qualified by a footnote. PMCPA ruled…
A UK resident saw a US Tysabri (POM) banner ad on telegraph.co.uk via retargeting. Panel initially found breaches, but the Appeal Board…
Anonymous pharmacist alleged an Apo-go nurse advisor changed Parkinson’s medicines without authority and failed to inform PDNSs. Panel found the programme a…
BMJ trial-tracker data suggested 1 Bayer “due” EUCTR trial lacked results (98.6% reported). Bayer showed the trial was withdrawn before enrolment and…
PMCPA case AUTH/3082/9/18 (Bristol-Myers Squibb) concerned clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (Code year…
BMJ analysis flagged a historic UK-site trial with results not posted to EUCTR by the EC guideline deadline. Panel found a Clause…
PMCPA found breaches after a Revolade IFR appointment email implied use in myelofibrosis and an internal brand-plan email referenced off‑licence presurgery use…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.